Intuitive Surgical (NASDAQ:ISRG) Price Target Cut to $600.00 by Analysts at Robert W. Baird

Intuitive Surgical (NASDAQ:ISRG) had its price target trimmed by Robert W. Baird from $707.00 to $600.00 in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

Several other research firms have also commented on ISRG. CICC Research began coverage on shares of Intuitive Surgical in a research note on Monday, January 27th. They set a “neutral” rating and a $550.00 target price for the company. Erste Group Bank raised shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a research note on Tuesday, November 19th. Leerink Partners increased their target price on shares of Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Bernstein Bank increased their target price on shares of Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a research note on Monday, January 27th. Finally, Citigroup upped their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $611.86.

Intuitive Surgical Price Performance

ISRG stock opened at $483.95 on Tuesday. Intuitive Surgical has a 12 month low of $364.17 and a 12 month high of $616.00. The firm has a market cap of $172.37 billion, a PE ratio of 75.50, a P/E/G ratio of 5.85 and a beta of 1.43. The firm has a 50 day simple moving average of $565.43 and a 200 day simple moving average of $531.90.

Insider Transactions at Intuitive Surgical

In other news, CFO Jamie Samath sold 94 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the transaction, the chief financial officer now owns 2,630 shares in the company, valued at $1,502,019.30. This represents a 3.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the transaction, the director now owns 12,275 shares in the company, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,754 shares of company stock worth $17,691,621 in the last 90 days. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Atala Financial Inc bought a new position in Intuitive Surgical in the 4th quarter worth $25,000. Berbice Capital Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth $26,000. Parvin Asset Management LLC bought a new position in Intuitive Surgical in the 4th quarter worth $26,000. BankPlus Trust Department bought a new position in Intuitive Surgical in the 4th quarter worth $28,000. Finally, Hurley Capital LLC bought a new position in Intuitive Surgical in the 4th quarter worth $28,000. Institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.